Saito and colleagues 5 utilized a comprehensive approach combining confocal microscopy with mass spectrometry to identify SAMHD1, an innate immune factor associated with autoimmunity and HIV infection, localized to lung immune complexes in human PAH. It is important to note that an unbiased metagenomic viral screen revealed a significant increase in HERV, specifically HERV-K, in PAH lung tissue, whereas no increase occurred in exogenous viruses. The authors discovered that HERV-K components, HERV-K (II) envelope and HERV-K dUTPase mRNA, are upregulated in PAH lungs, notably in pulmonary macrophages and circulating monocytes. Mechanistically, they found that recombinant HERV-K dUTPase can induce SAMDH1 expression in pulmonary arterial endothelial cells and monocytes, driving endothelial apoptosis and monocytic expression of inflammatory cytokines. In vivo, injections of recombinant dUTPase in rats resulted in hemodynamic, histological, and inflammatory alterations consistent with PAH.
Collectively, these findings represent an innovative and substantial step forward in our understanding of viral pathogenesis in vascular inflammation and PAH ( Figure) . However, we are just beginning to obtain comprehensive, cause-and-effect proof of this pathobiology. Historically, the generation of rigorous scientific evidence for a direct pathogenic role for any endogenous retrovirus has been challenging. In part, this stems from the undefined fundamental biology and modes of activation of these genetic sequences. Their nearly ubiquitous prevalence in the general population, with multiple insertion sites as well as complete and incomplete open reading frames, also make straightforward comparative studies difficult. Additionally, it is not known how HERV-K is upregulated in PAH. Saito and colleagues 5 found that HERV-K mRNA expression increased in monocytes after genotoxic lipopolysaccharide exposure. In contrast, inducible pluripotent stem cells from patients with PAH exhibited higher HERV-K dUPTase mRNA levels without any inflammatory stimulation. Although the definitive molecular driver(s) of HERV-K dUTPase expression remains undefined, at the least, these data suggest a more complex cell type-and perhaps context-specificity of this regulation. It is also not clear whether other endogenous retroviruses may display the same activity as HERV-K in PAH or whether HERV-K carries unique pathogenic activity for the pulmonary vasculature. It would be interesting to search for endogenous retrovirus activity in PAH in other mammals, particularly those with known genetic predisposition, such as brisket disease in cattle. 7 It is also notable that many human diseases associated with HERV-K have not Figure. HERV-K may initiate or propagate the inflammation that defines pulmonary arterial hypertension. Saito and colleagues propose a role for HERV-K in the pathogenesis of PAH. Specifically, HERV-K components induce SAMDH1 expression, resulting in cytokine release, endothelial apoptosis, and B-cell activation. How HERV-K is activated or its diagnostic and therapeutic implications are still undefined. HERV-K indicates human endogenous retrovirus K; IL, interleukin; PAH, pulmonary arterial hypertension; and TNF, tumor necrosis factor. been linked to PAH, such as neuropsychiatric illnesses, thus providing an opportunity for future studies to search for a molecular explanation for that discrepancy. Finally, given the historical difficulties of proving a critical role for specific exogenous viruses in PAH, it will be imperative to corroborate these findings in a larger cohort of patients, hopefully with stratification of different subtypes of PAH and pulmonary hypertension in general.
Overall, this publication, which is built on prior work in both chronic inflammation and viral pathogenesis in PAH, highlights an intriguing new direction of discovery regarding the pathobiology of endogenous retroviruses. If relevant molecular mechanisms can be established in future work, substantial opportunity is available to design new diagnostic markers of PAH by tracking the activation of HERV-K. Furthermore, given the rapid advances of CRISPR-Cas9 gene editing tools in vivo for endogenous retroviruses in mammals, 8 HERV-K may represent an exceptionally novel therapeutic target for PAH in the not-so-distant future.
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